Oral and injectable medications for the treatment of erectile dysfunction |
| |
Authors: | Carson C C |
| |
Institution: | (1) Division of Urology, University of North Carolina, 427 Burnett-Womack CB 7235, 27599-7235 Chapel Hill, NC, USA |
| |
Abstract: | The treatment of erectile dysfunction has changed dramatically over the past two decades. The introduction of the oral agent
sildenafil 2 years ago has revolutionized the treatment of men with compromised erections and has met with expected success
and low morbidity. Sildenafil is effective in most men with erectile dysfunction in the general population and in select populations,
such as men with spinal cord injury, diabetes mellitus, and patients who have had nerve-sparing radical prostatectomy. It
is safe in the general population as well as in many men with cardiac disease. Other newer medications are in trial and may
soon be available to supplement treatment with sildenafil. Oral phentolamine, apomorphine, newer phosphodiesterase type-5
inhibitors, and topical agents are currently in phase 3 trials. These agents, in addition to newer intraurethral and indictable
agents, may assist men with erectile dysfunction and rescue those in whom sildenafil is ineffective or in whom untoward side
effects of sildenafil reduce its effectiveness. The 21st century will witness many additional agents designed for specific
patients with specific conditions causing erectile dysfunction. We can expect these oral agents, assisted by topical and injectable
agents, to successfully restore erectile function in the majority of men suffering from erectile dysfunction. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|